Company Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.
The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases.
In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy.
Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials.
The company was founded in 1986 and is based in Cranbury, New Jersey.
| Country | United States |
| Founded | 1986 |
| IPO Date | Oct 28, 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Dr. Carl Spana Ph.D. |
Contact Details
Address: 4b Cedar Brook Drive Cranbury, New Jersey 08512 United States | |
| Phone | 609-495-2200 |
| Website | palatin.com |
Stock Details
| Ticker Symbol | PTN |
| Exchange | NYSEAMERICAN |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0000911216 |
| CUSIP Number | 696077403 |
| ISIN Number | US6960775020 |
| Employer ID | 95-4078884 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carl Spana Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Stephen T. Wills CPA, MST | Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer and Secretary |
| Burns McClellan | Vice President of Investor Relations |
| Stephen A. Slusher Esq. | Chief Legal Officer |
| Dr. Michael B. Raizman M.D. | Chief Medical Officer |
| James E. Hattersley | Senior Vice President of Business Development |
| John Dodd Ph.D. | Senior Vice President of Preclinical Development |
| Robert Jordan | Senior Vice President of Program Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2024 | EFFECT | Notice of Effectiveness |
| Mar 28, 2024 | 424B3 | Prospectus |
| Mar 14, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 4, 2024 | 144 | Filing |
| Feb 15, 2024 | 8-K | Current Report |
| Feb 14, 2024 | 10-Q | Quarterly Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 1, 2024 | 8-K | Current Report |
| Feb 1, 2024 | 424B5 | Filing |
| Dec 20, 2023 | 8-K | Current Report |